Institution identification

PURI

https://redirect.ema.europa.eu/resource/23758

Institution ID

23758

Institution full name and acronym

OXON Epidemiology

Institution countries

Spain
United Kingdom

Type of institution

Laboratory/Research/Testing facility
Non-Pharmaceutical company

Institution website

ENCePP partner

Yes
Institution description
OXON Epidemiology is a full-service global scientific service provider specialising in global safety and outcomes field & database observational studies.
• Prospective/registry studies
• Cross-sectional studies
• Risk minimisation surveys
• Retrospective chart review studies
• Database studies
• Hybrid studies

With a staff that are co-authors of (x7) Lancet,(x1) JAMA and (x3) BMJ articles, strong links with leading EU academic database epidemiologists, and a long-term alliance with a top tier CRO,OXON competes on a global scale providing a unique blend of observational science and operational excellence to help clients worldwide obtain high quality real-world data for improving patients and public health in major therapeutic areas, particularly.
• Oncology / Haematology
• Cardiovascular disease
• Metabolic / Diabetes / Bone
• Gastroenterology
• Immunology
• Vaccines / Infectious diseases
• Neuroscience
• Paediatrics
• Respiratory disease
• Orphan conditions
• Urology / Renal
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection (208165)
A retrospective study to evaluate the clinical effectiveness and safety of treatments for Covid-19 hospitalised patients and to determine prognostic factors. (RAPID COVID-19)
Characterising the safety profile of lurasidone in clinical practice: A drug utilisatio and safety study using a United Kingdom primary care database
Disease progression and resource utilization in treated relapse/refractory multiple myeloma in Spain (PREMIERE)
Evaluation of the effectiveness of Penthrox® (methoxyflurane) educational tools adopted as additional risk minimisation measures: Healthcare professional and Patient Survey (Penthrox-Survey)
Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and subcutaneous formulation Patient Alert Cards in patients with rheumatoid arthritis in a sample of European Economic Area countries
Evaluation of the effectiveness of the belatacept (Nulojix®) Patient Alert Card in patients following renal transplantation in European Economic Area countries.
Localised Neuropathic Pain (LNP) managed in the primary care setting in France, Ireland, Italy, Spain, and the United Kingdom: A cross-sectional study of prevalence, clinical characteristics, treatment patterns and patient’s reported outcomes
Longitudinal Analyses of Blood Lipids and Future Risk of Dementia in CPRD (Lipids and dementia)
Longitudinal Analyses of Blood Pressure and Risk of Alzheimer´s disease and Vascular Dementia in 2.6 million people over 2 decades (BP and Dementia)
Longitudinal Analyses of Body Mass Index and Risk of Parkinson's Disease in 2 million people over 2 decades (BMI and Parkinson´s disease)
Myozyme (alglucosidase alfa) Safety Information Packet effectiveness evaluation: a health care professional survey
Non-interventional study with Binosto 70 mg effervescent tablets once weekly investigating gastro-intestinal events and medication errors (Gastro-PASS)
Post Authorisation Safety Study (PASS) to Evaluate the Risks of Hepatotoxicity and Nephrotoxicity from Administration of Methoxyflurane (Penthrox®) for Pain Relief in Hospital Accident & Emergency Departments in the United Kingdom (Penthrox-PASS)
Real-time systematic review and meta-analysis of non-randomised comparative treatment studies for COVID-19
Retrospective Cohort Study of Certolizumab Pegol (Cimzia®) and Other Subcutaneous Anti-Tumour Necrosis Factor-Alpha Drugs in Rheumatoid Arthritis to Explore Usage Patterns and Clinical Outcomes in daily clinical practice in the United Kingdom
Survey to Evaluate the Effectiveness of Risk Minimisation Measures for Atezolizumab Use in the European Union
Systematic Review and meta-analysis of PASS Studies Assessing the Effectiveness of Risk Minimisation Measures
Zanamivir 10mg/ml solution for infusion pregnancy registry: an observational study of the safety of zanamivir 10mg/ml solution for infusion exposure in pregnant women with complicated influenza and their offspring (208140)